Biotech Values

[RNsidersbuying]

ARPO 1.30 - accumulating on two partially funded covid therapeutic trials and a few more pans hot on the fire...

https://finance.yahoo.com/news/aerpio-announces-first-patient-dosed-200100014.html

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14327189&RcvdDate=8/12/2020&CoName=AERPIO%20PHARMACEUTICALS,%20INC.&FormType=8-K&View=html

About Razuprotafib (formerly known as AKB-9778)

Razuprotafib binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity contributes to vascular instability in many diseases including diabetes and more recently has been shown to contribute to the development of increased IOP and glaucoma. Razuprotafib activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist) and may be the most efficient pharmacologic approach to maintain normal Tie2 activation. Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy. In addition, a subcutaneous formulation of razuprotafib is being explored for its therapeutic potential in treating or preventing ARDS associated with COVID-19.